Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OGN Organon & Co.	$10.07 -0.3%	$9.63	$8.01 ▼ $23.10	$2.63B	0.6	3.54 million shs	2.84 million shs
PTCT PTC Therapeutics	$46.32 -1.6%	$48.89	$29.01 ▼ $58.38	$3.73B	0.5	873,058 shs	783,660 shs
RYTM Rhythm Pharmaceuticals	$87.27 -0.6%	$69.51	$40.61 ▼ $94.80	$5.59B	2.26	991,858 shs	388,632 shs
WVE WAVE Life Sciences	$8.39 -2.0%	$6.97	$5.04 ▼ $16.74	$1.33B	-1.01	1.58 million shs	1.00 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OGN Organon & Co.	+2.88%	+4.69%	+2.72%	-16.74%	-53.00%
PTCT PTC Therapeutics	+1.49%	-2.20%	-5.08%	-4.98%	+40.33%
RYTM Rhythm Pharmaceuticals	-0.01%	-3.97%	+41.33%	+39.45%	+76.33%
WVE WAVE Life Sciences	+7.94%	+9.46%	+22.99%	+26.07%	+36.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OGN Organon & Co.	4.7622 of 5 stars	3.3	3.0	1.7	3.7	2.3	3.3	1.9
PTCT PTC Therapeutics	4.4237 of 5 stars	4.3	1.0	0.0	4.4	2.8	0.8	1.3
RYTM Rhythm Pharmaceuticals	3.2498 of 5 stars	2.5	1.0	0.0	4.3	2.8	0.8	0.6
WVE WAVE Life Sciences	4.6105 of 5 stars	3.5	2.0	0.0	4.8	3.4	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OGN Organon & Co.	2.50	Moderate Buy	$18.00	78.82% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	40.33% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	5.34% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.15	140.21% Upside

Current Analyst Ratings Breakdown

Latest WVE, RYTM, PTCT, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/16/2025	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OGN Organon & Co.	$6.40B	0.41	$4.91 per share	2.05	$1.83 per share	5.50
PTCT PTC Therapeutics	$806.78M	4.55	N/A	N/A	($14.24) per share	-3.25
RYTM Rhythm Pharmaceuticals	$130.13M	42.67	N/A	N/A	$0.35 per share	249.34
WVE WAVE Life Sciences	$108.30M	12.05	N/A	N/A	$1.37 per share	6.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OGN Organon & Co.	$864M	$2.88	3.50	2.69	1.05	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.12	N/A	N/A	33.56%	-78.56%	32.11%	8/7/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	7/30/2025 (Estimated)

Latest WVE, RYTM, PTCT, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	$173.01 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
7/30/2025	Q2 2025	WVE WAVE Life Sciences	-$0.28	N/A	N/A	N/A	$11.52 million	N/A
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OGN Organon & Co.	$0.08	0.79%	N/A	2.78%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Latest WVE, RYTM, PTCT, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OGN Organon & Co.	16.49	1.67	1.15
PTCT PTC Therapeutics	N/A	3.89	3.85
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OGN Organon & Co.	77.43%
PTCT PTC Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
OGN Organon & Co.	1.96%
PTCT PTC Therapeutics	5.50%
RYTM Rhythm Pharmaceuticals	6.10%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

WVE, RYTM, PTCT, and OGN Headlines

Recent News About These Companies

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

July 23 at 8:30 AM | globenewswire.com

Hussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 19, 2025 | marketbeat.com

Principal Financial Group Inc. Acquires 59,399 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 19, 2025 | marketbeat.com

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views

July 16, 2025 | benzinga.com

Citigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

July 16, 2025 | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?

July 16, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at Citigroup

July 16, 2025 | marketbeat.com

Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions

July 15, 2025 | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

July 15, 2025 | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE, RYTM, PTCT, and OGN Company Descriptions

Organon & Co. NYSE:OGN

$10.07 -0.03 (-0.34%)

Closing price 03:59 PM Eastern

Extended Trading

$10.04 -0.02 (-0.21%)

As of 07:56 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

PTC Therapeutics NASDAQ:PTCT

$46.32 -0.76 (-1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$47.12 +0.81 (+1.74%)

As of 04:20 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$87.27 -0.54 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$87.24 -0.02 (-0.03%)

As of 04:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

WAVE Life Sciences NASDAQ:WVE

$8.39 -0.17 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$8.40 +0.01 (+0.12%)

As of 06:06 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time